2023
Torsemide vs Furosemide After Discharge and All-Cause Mortality in Patients With Heart Failure—Reply
Mentz R, DeWald T, Velazquez E. Torsemide vs Furosemide After Discharge and All-Cause Mortality in Patients With Heart Failure—Reply. JAMA 2023, 329: 1704-1704. PMID: 37191705, DOI: 10.1001/jama.2023.5291.Peer-Reviewed Original ResearchEffect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure
Mentz R, Anstrom K, Eisenstein E, Sapp S, Greene S, Morgan S, Testani J, Harrington A, Sachdev V, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Velazquez E, Adams K, Bhatt K, DeWald T, Axsom K, Murthy S, Rich J, Testani J, Smith B, Vader J, McCulloch M, Skopicki H, Psotka M, Heroux A, Lala-Trindade A, Stevens G, Tang W, Lev Y, William P, Eberly A, Gottleib S, Haught W, Grafton G, Larned J, Tejwani L, Mody F, Krim S, Robinson M, Fang J, Adler A, Bell A, Banerjee D, Ruiz Duque E, Mizyed A, Rommel J, Arhinful J, Goyal P, Hall M, Hummel S, Shetty S, Haas D, Vilaro J, Alexy T, Herre J, Clark J, Ambrosy A, Gaglianello N, Ramasubbu K, Meadows J, Tabtabai S, Sherwood M, Hasni S, D'Urso M, Muneer B, Dunlap S, Davis W, Friedman D, Guglin M, Ferguson A, Abbate A, Smart F. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure. JAMA 2023, 329: 214-223. PMID: 36648467, PMCID: PMC9857435, DOI: 10.1001/jama.2022.23924.Peer-Reviewed Original ResearchConceptsCause mortalityHeart failureTorsemide groupFurosemide groupTotal hospitalizationsCause hospitalizationEffects of torsemideDiuretic strategyPrespecified subgroupsSecondary outcomesEjection fractionMedian agePrimary outcomeHospitalizationMAIN OUTCOMEPatientsFurosemideMortalityMonthsTorsemidePrimary hypothesisSignificant differencesFinal dateOutcomesTrials
2019
Community Health Workers Improve Linkage to Hypertension Care in Western Kenya
Vedanthan R, Kamano JH, DeLong AK, Naanyu V, Binanay CA, Bloomfield GS, Chrysanthopoulou SA, Finkelstein EA, Hogan JW, Horowitz CR, Inui TS, Menya D, Orango V, Velazquez EJ, Were MC, Kimaiyo S, Fuster V. Community Health Workers Improve Linkage to Hypertension Care in Western Kenya. Journal Of The American College Of Cardiology 2019, 74: 1897-1906. PMID: 31487546, PMCID: PMC6788970, DOI: 10.1016/j.jacc.2019.08.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntihypertensive AgentsBlood PressureBlood Pressure DeterminationCluster AnalysisCommunicationCommunity Health ServicesCommunity Health WorkersFemaleHealth BehaviorHealth PromotionHealth Services AccessibilityHealth Services ResearchHumansHypertensionKenyaMaleMedication AdherenceMiddle AgedRisk FactorsSmartphoneSystoleTelemedicineConceptsCommunity health workersElevated blood pressureBlood pressureSystolic BPUsual careHealth workersHypertension careCovariate-adjusted mixed effects modelAverage overall followBaseline systolic BPHypertension care programCo-primary outcomesSystolic blood pressureSBP reductionHypertension controlOverall followSBP changeRisk factorsCare programLinkage of individualsCareMixed effects modelsGreater reductionMobile healthMortalityDoes prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial
Nicolau JC, Stevens SR, Al-Khalidi HR, Jatene FB, Furtado RHM, Dallan LAO, Lisboa LAF, Desvigne-Nickens P, Haddad H, Jolicoeur EM, Petrie MC, Doenst T, Michler RE, Ohman EM, Maddury J, Ali I, Deja MA, Rouleau JL, Velazquez EJ, Hill JA. Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial. International Journal Of Cardiology 2019, 291: 36-41. PMID: 30929973, PMCID: PMC6579621, DOI: 10.1016/j.ijcard.2019.03.029.Peer-Reviewed Original ResearchConceptsPrior percutaneous coronary interventionPercutaneous coronary interventionLeft ventricular ejection fractionSTICH trialCV hospitalizationCV mortalityCause mortalityMedical treatmentSuperiority of CABGOutcomes of patientsSurgical coronary revascularizationCoronary artery bypassVentricular ejection fractionArtery bypassCoronary revascularizationCoronary interventionCoronary angioplastyEjection fractionMedian timeWorse prognosisRandomized treatmentCABGHospitalizationMortalityPatients
2017
Comparison of Clinical Characteristics and Outcomes of Patients With Versus Without Diabetes Mellitus and With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular Disease)
Banks A, Broderick S, Chiswell K, Shaw L, Devore A, Fiuzat M, O'Connor C, Felker GM, Velazquez E, Mentz R. Comparison of Clinical Characteristics and Outcomes of Patients With Versus Without Diabetes Mellitus and With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular Disease). The American Journal Of Cardiology 2017, 119: 1703-1709. PMID: 28395884, DOI: 10.1016/j.amjcard.2017.02.053.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseAngina pectorisDiabetes mellitusDM statusCause mortalityMultivariable Cox regressionOutcomes of patientsDifferent prognostic implicationsSeverity of diseaseAP statusCV hospitalizationClinical characteristicsArtery diseaseCoronary angiographyDM patientsClinical outcomesCox regressionPrognostic implicationsPrognostic utilityRevascularizationSimilar riskPatientsRisk adjustmentMortalityPectoris
2015
Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)
Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O'Connor CM. Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). The American Journal Of Cardiology 2015, 117: 404-411. PMID: 26704029, PMCID: PMC4718787, DOI: 10.1016/j.amjcard.2015.10.059.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedCause of DeathDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesFurosemideGlobal HealthHeart FailureHospitalizationHumansMaleMiddle AgedRetrospective StudiesSodium Potassium Chloride Symporter InhibitorsStroke VolumeSulfonamidesSurvival RateTorsemideTreatment OutcomeConceptsHeart failureChoice of diureticAcute heart failureDecompensated heart failureNatriuretic peptide levelsLow ejection fractionComparative effectiveness trialHF hospitalizationBlood pressureEjection fractionUnadjusted analysesAcute studyClinical effectivenessEffectiveness trialPeptide levelsPatientsFurosemideSimilar outcomesInverse probabilityPotential pharmacologicTorsemideDiureticsMortalityTrialsFailureCurrent and emerging modalities for detection of cardiotoxicity in cardio-oncology
Khouri MG, Klein MR, Velazquez EJ, Jones LW. Current and emerging modalities for detection of cardiotoxicity in cardio-oncology. Future Cardiology 2015, 11: 471-484. PMID: 26235924, PMCID: PMC5558528, DOI: 10.2217/fca.15.16.Peer-Reviewed Original ResearchConceptsEarly detectionLife-saving cancer therapyCurative-intent therapyCancer-specific mortalityCancer-specific survivalCardiovascular risk factorsDetection of cardiotoxicityFunctional capacity testingNovel adjuvant therapyDegree of cardiotoxicityAdjuvant therapyCardiovascular morbidityCardiovascular mortalityCardiovascular dysfunctionCardiovascular injuryBlood biomarkersRisk factorsEarly preventionCancer treatmentCardiotoxicityTherapyMortalityCancer therapyDiagnostic toolInjuryTorsemide Versus Furosemide in Heart Failure Patients
Mentz RJ, Buggey J, Fiuzat M, Ersbøll MK, Schulte PJ, DeVore AD, Eisenstein EL, Anstrom KJ, O'Connor C, Velazquez EJ. Torsemide Versus Furosemide in Heart Failure Patients. Journal Of Cardiovascular Pharmacology 2015, 65: 438-443. PMID: 25945862, PMCID: PMC4423558, DOI: 10.1097/fjc.0000000000000212.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedComorbidityDatabases, FactualFemaleFurosemideHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedNorth CarolinaRetrospective StudiesRisk FactorsSex FactorsSodium Potassium Chloride Symporter InhibitorsSulfonamidesTertiary Care CentersTorsemideTreatment OutcomeUltrasonographyConceptsHeart failure patientsFailure patientsEffects of torsemideFurosemide-treated patientsMore comorbiditiesCause mortalityBaseline characteristicsProspective trialHeart failureLoop diureticsResidual confoundingPatientsDuke HospitalFurosemideRisk adjustmentTorsemideMortalityLab databaseComorbiditiesDiureticsHospitalTrials
2014
Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy An Analysis From the STICH Trial (Surgical Treatment for Ischemic Heart Failure)
Stewart RA, Szalewska D, She L, Lee KL, Drazner MH, Lubiszewska B, Kosevic D, Ruengsakulrach P, Nicolau JC, Coutu B, Choudhary SK, Mark DB, Cleland JG, Piña IL, Velazquez EJ, Rynkiewicz A, White H. Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy An Analysis From the STICH Trial (Surgical Treatment for Ischemic Heart Failure). JACC Heart Failure 2014, 2: 335-343. PMID: 25023813, PMCID: PMC4127151, DOI: 10.1016/j.jchf.2014.02.009.Peer-Reviewed Original ResearchConceptsCoronary artery bypass graft surgeryIschemic left ventricular dysfunctionLeft ventricular dysfunctionArtery bypass graft surgeryBypass graft surgeryPoor exercise capacityExercise capacityMedical therapyVentricular dysfunctionSTICH trialGraft surgeryBetter exercise capacityWalk testMedical managementPrognostic significanceTreatment allocationPhysical activityPatientsEarly riskHigh mortalityMortalityTherapyDysfunctionSurgeryTrials
2011
Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, Drozdz J, Farsky PS, Feldman AM, Doenst T, Michler RE, Berman DS, Nicolau JC, Pellikka PA, Wrobel K, Alotti N, Asch FM, Favaloro LE, She L, Velazquez EJ, Jones RH, Panza JA. Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction. New England Journal Of Medicine 2011, 364: 1617-1625. PMID: 21463153, PMCID: PMC3290901, DOI: 10.1056/nejmoa1100358.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular DiseasesCombined Modality TherapyCoronary Artery BypassCoronary Artery DiseaseEchocardiography, StressFemaleFollow-Up StudiesHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial IschemiaMyocardiumProportional Hazards ModelsStatistics, NonparametricTomography, Emission-Computed, Single-PhotonVentricular Dysfunction, LeftConceptsCoronary artery diseaseVentricular dysfunctionMedical therapyMyocardial viabilityArtery diseaseViable myocardiumSurvival benefitBaseline variablesIschemic left ventricular dysfunctionDifferential survival benefitSubstudy of patientsCoronary artery bypassLeft ventricular dysfunctionDobutamine echocardiographyUnderwent assessmentPatientsCABGDysfunctionTreatment assignmentTherapyMyocardiumDiseaseGreater likelihoodMortalityTrialsPredictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction
Thune JJ, Signorovitch JE, Kober L, McMurray JJ, Swedberg K, Rouleau J, Maggioni A, Velazquez E, Califf R, Pfeffer MA, Solomon SD. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. European Journal Of Heart Failure 2011, 13: 148-153. PMID: 21037250, DOI: 10.1093/eurjhf/hfq194.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedCaptoprilCause of DeathConfidence IntervalsDrug Therapy, CombinationFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPredictive Value of TestsPrognosisProportional Hazards ModelsRecurrenceRisk AssessmentSeverity of Illness IndexSex FactorsSurvival AnalysisTetrazolesTime FactorsValineValsartanVentricular Dysfunction, LeftConceptsRecurrent myocardial infarctionFirst myocardial infarctionRisk of deathLeft ventricular dysfunctionMyocardial infarctionVentricular dysfunctionHeart failurePrognostic impactOne-year mortalityGlomerular filtration rateEarly reinfarctionLate reinfarctionTrial cohortUnstable anginaProlong survivalMedian timeMI survivorsFiltration ratePatientsContemporary managementContemporary treatmentInfarctionMortalityReinfarctionDeath
2010
Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial
Nilsson KR, Al-Khatib SM, Zhou Y, Pieper K, White HD, Maggioni AP, Kober L, Granger CB, Lewis EF, McMurray JJ, Califf RM, Velazquez EJ. Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart 2010, 96: 838. PMID: 20406769, DOI: 10.1136/hrt.2009.180182.Peer-Reviewed Original ResearchConceptsRhythm control strategyAcute Myocardial Infarction trialMyocardial Infarction trialAtrial fibrillationMyocardial infarctionRate control strategyEarly mortalityAnti-arrhythmic drug therapyTreatment of AFPeri-infarct periodIncidence of strokeManagement of patientsRisk of deathLate mortalityPatient populationDrug therapyCox modelPatientsMortalityInfarctionStrokeValsartanTrialsDeathDays
2008
Impact of Left Ventricular Dysfunction on Hospital Mortality Among Patients Undergoing Elective Percutaneous Coronary Intervention
Wallace TW, Berger JS, Wang A, Velazquez EJ, Brown DL. Impact of Left Ventricular Dysfunction on Hospital Mortality Among Patients Undergoing Elective Percutaneous Coronary Intervention. The American Journal Of Cardiology 2008, 103: 355-360. PMID: 19166689, DOI: 10.1016/j.amjcard.2008.09.088.Peer-Reviewed Original ResearchConceptsElective percutaneous coronary interventionPercutaneous coronary interventionHospital mortalityEjection fractionCoronary interventionOdds ratioLeft ventricular systolic dysfunctionHospital mortality increasesReduced ejection fractionRetrospective cohort studyVentricular systolic dysfunctionLeft ventricular dysfunctionLow ejection fractionLV ejection fractionAdjusted hospital mortalitySystolic dysfunctionVentricular dysfunctionCohort studyMultivariate adjustmentMedical therapyEF groupPatientsMortalityOutcome variablesMortality increases
2004
Prognostic usefulness of left ventricular thrombus by echocardiography in dilated cardiomyopathy in predicting stroke, transient ischemic attack, and death
Crawford TC, Smith WT, Velazquez EJ, Taylor SM, Jollis JG, Kisslo J. Prognostic usefulness of left ventricular thrombus by echocardiography in dilated cardiomyopathy in predicting stroke, transient ischemic attack, and death. The American Journal Of Cardiology 2004, 93: 500-503. PMID: 14969636, DOI: 10.1016/j.amjcard.2003.10.056.Peer-Reviewed Original Research